- Home
- DT vs RPRX Comparison
DT vs RPRX Comparison
Compare DT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- RPRX
- Stock Information
- Founded
- DT 2005
- RPRX 1996
- Country
- DT United States
- RPRX United States
- Employees
- DT N/A
- RPRX N/A
- Industry
- DT Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- DT Technology
- RPRX Health Care
- Exchange
- DT Nasdaq
- RPRX Nasdaq
- Market Cap
- DT 15.2B
- RPRX 16.2B
- IPO Year
- DT 2019
- RPRX 2020
- Fundamental
- Price
- DT $46.75
- RPRX $39.23
- Analyst Decision
- DT Buy
- RPRX Strong Buy
- Analyst Count
- DT 22
- RPRX 3
- Target Price
- DT $62.14
- RPRX $46.00
- AVG Volume (30 Days)
- DT 3.4M
- RPRX 3.7M
- Earning Date
- DT 11-05-2025
- RPRX 11-05-2025
- Dividend Yield
- DT N/A
- RPRX 2.21%
- EPS Growth
- DT 208.33
- RPRX N/A
- EPS
- DT 1.66
- RPRX 1.75
- Revenue
- DT $1,852,532,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- DT $20.09
- RPRX $36.16
- Revenue Next Year
- DT $14.56
- RPRX $2.04
- P/E Ratio
- DT $28.10
- RPRX $22.68
- Revenue Growth
- DT 18.50
- RPRX 3.70
- 52 Week Low
- DT $39.30
- RPRX $24.05
- 52 Week High
- DT $63.00
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- DT 41.04
- RPRX 59.26
- Support Level
- DT $45.84
- RPRX $38.39
- Resistance Level
- DT $47.60
- RPRX $40.01
- Average True Range (ATR)
- DT 1.63
- RPRX 1.26
- MACD
- DT -0.27
- RPRX 0.12
- Stochastic Oscillator
- DT 26.22
- RPRX 63.19
About DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.